IL-17

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Associated T Cells in Axial Spondyloarthritis https://t.co/RPD7FkgEdQ anti-TRVB and anti-TRAV for your B27 AxSpA patients ( and needs looking at B27 positive PsA ) watch this space

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Ass…

Deep learning DIXON MRI of SI joints (n=76, suspected axSpA): 5:24 min vs 19:49 for standard MRI (>70% faster). AUC 0.86 vs 0.87; specificity 98% vs 89%, but sensitivity 74% vs 84%. Faster, more accessible screening, with a sensitivity trade-off. #APLAR26 @RheumNow https://t.co/YUTQwcDmsz

Italian retrospective study of 562 plaque psoriasis Rx w/ biologics - 34% were obese. Primary Rx failure signif. more w/ obesity (17% vs 6%; HR 2.75). A 5 kg/m2 BMI incr assoc w/ 37% higher risk. Lower risk of failure w/ IL-17i (HR 0.49) & IL-23i (HR 0.47). Obesity not assoc w/ https://t.co/fUik6pBcnq

Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 https://t.co/KtH0AIatdq

Novartis receives European Commission approval for Cosentyx® in polymyalgia rhe…

Article

2026 BSR Guideline for the Treatment of Polymyalgia Rheumatica

Jack Cush, MD Oct 27, 2026

Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients

EBR Journal Club: Secukinumab in Polymyalgia Rheumatica (REPLENISH) The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. https://t.co/uejuXKsrWD https://t.co/SqtsxK6etR

EBR Journal Club: Secukinumab in Polymyalgia Rheumatica (REPLENISH) | RheumNow

Article

EBR Journal Club: Secukinumab in Polymyalgia Rheumatica (REPLENISH)

Michael Putman, MD, MSCI Oct 22, 2026

This edition: REPLENISH (secukinumab in polymyalgia rheumatica). The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. Each review covers four domains: Does this apply to my patients? What is the risk of bias?

EADV abstract showed daxdilimab (anti-ILT7; on plasmacytoid dendritic cells) was effective in mod-severe discoid lupus. Ph II RCT 72 refract. DLE RCT; DAX vs PBO - ↓ CLASI-A vs placebo @24 wks. wk 4 ≥50% CLASI-A ~62% vs 24% https://t.co/gJ4drxErGD https://t.co/TexG55dDBL

In Phase 2 Trial, Daxdilimab Reduces Disease Activity in Moderate-to-Severe Dis…

Funny! Dr. Glaucomflecken explains the REPLENISH trial -secukinumab for the treatment of polymyalgia rheumatica https://t.co/7JDoMDJzeD https://t.co/ZBMcheSeCv

Dr. Glaucomflecken Explains: Secukinumab in Polymyalgia Rheumatica | NEJM

Article

Don’t Hold the JAK (10.9.2026)

Jack Cush, MD Oct 09, 2026

On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients.

Article

Predicting and Preventing Psoriatic Arthritis

Jack Cush, MD Oct 07, 2026

Psoriatic arthritis is often underdiagnosed in those with psoriasis (PsO), leading to diagnostic delays an undertreatment. While certain factors in PsO portend a future PsA risk, a predictive profile and early intervention algorithm do not

Article

Remission – Believe it or Not (10.2.2026)

Jack Cush, MD Oct 02, 2026

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Do biologic Rx lower risk of PsA? Metanalysis (15 studies, 124,138 psoriasis pts, 778K PYrs F/U), showed Biologic use assoc w/ lower risk of PsA (HR 0.54); best for IL-17i (0.65) & IL-12/23 or IL-23i (0.46) vs TNFi. IL-23i superior to IL-17i (HR 0.67) https://t.co/pjZZJ8yq9A https://t.co/yIwQs2FwLW

Impact of Biologic Therapies on the Risk of Progression from Psoriasis to Psori…

Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein https://t.co/5QPBdZivxC https://t.co/VfV873Lire

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO…

52 VEXAS pts Rx w/ IL‐1i, IL‐6i, or JAKi therapy judged as compl Resp (CR), partial (PR), Failure (TF). @ 6mos: 3/19 IL‐6i had CR, 4/19 PR, 7/19 TF. JAKi had 2/17 CR, 3/17 PR, 6/17 TF. No CR w/ IL‐1i or TNFαi, only 1/5 IL‐1i patients experienced PR. Only IL‐6i & JAKi had https://t.co/wqogmfeAru

Article

Rheumatology Pay Up (9.25.2026)

Jack Cush, MD Sep 25, 2026

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

17 Sept EMA CHMP recommended marketing authorisation for secukinumab (Cosentyx) in the treatment of polymyalgia rheumatica. BUT- not yet EMA approved in the EU. https://t.co/ZGUSbw06vX https://t.co/EqRwpT8Sxo

Cosentyx - opinion on variation to marketing authorisation | European Medicines…

Chinese 52 wk study of XKH004, a novel, SC, humanized anti-17A/F in 323 active AS pts Rx q4 wks vs PBO. @ Wk 16, XKH004 was superior for ASAS40 (45.4% vs 19.4%; P<0.001), improved to 66% by wk 52. https://t.co/f7w41m4QZy https://t.co/LELo52zUb7

https://buff.ly/6ZIzPu2

Article

Early RA Referral Clinics Work (9.18.2026)

Jack Cush, MD Sep 18, 2026

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Chinese 52 wk study of XKH004, a novel, SC, humanized anti-17A/F in 323 active AS pts Rx q4 wks vs PBO. @ Wk 16, XKH004 was superior for ASAS40 (45.4% vs 19.4%; P<0.001), improved to 66% by wk 52. https://t.co/f7w41m4QZy https://t.co/5MPm388kau

https://buff.ly/6ZIzPu2

FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis. Regulatory decision expected 1st quarter 2027. Supported by phase 3 RCTs, 3000 pts -- LATITUDE PsO 3001 and 3002 clinical trials. https://t.co/o7oqxSXHSw https://t.co/evzPtaTWI4

FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis | Patient Care O…

Together PsA 52 wk data (n 271): ACR50 plus >10% wt loss - 39.2% w/ Taltz & Zepbound vs 1.7% w/ Taltz alone. Together PsO trial results (n 274): PASI100 plus >10% wt loss - 30.6% w/ Taltz & Zepbound vs 4.4% w/ Taltz alone. https://t.co/27TBZyL8l1 https://t.co/VdQJALdoJt

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used…

True or False: A meta-analysis of hidradenitis suppurativa patients showed IL-17 inhibitors significantly increased IBD risk compared to placebo. See if you got it right in this week's RheumIQ quiz at https://t.co/UaXqHKWizt.

RheumIQ Weekly Quiz | RheumNow

Article

A Day of Infamy (9.11.2026)

Jack Cush, MD Sep 11, 2026

Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis. And take this week's RheumIQ quiz

Meta-analysis 24 studies (3015 hidradenitis suppurativa pts) taking IL-17 inhibitor, IBD adverse events were rare, w/ no difference in IBD risk betw IL-17i & PBO (0.23% vs 0 of 2572 vs 1066 pts respectively) thru wk 16. The reported assocn of IL-17 inhibitors w/ IBD risk is https://t.co/kDwR5Fc1zI